1
|
Sampaio RNR. Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion. Expert Opin Pharmacother 2023; 24:153-158. [PMID: 36503319 DOI: 10.1080/14656566.2022.2157208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Raimunda Nonata Ribeiro Sampaio
- Dermatology Service of the University Hospital and Dermatomicology Laboratory of the Faculty of Medicine (FM)- (UnB).,Postgraduate course in Medical Sciences at FM-UnB.,Postgraduate course in Health Sciences at Faculty of Health Sciences-UnB
| |
Collapse
|
2
|
Gallo-Francisco PH, Brocchi M, Giorgio S. Leishmania and its relationships with bacteria. Future Microbiol 2022; 17:199-218. [PMID: 35040703 DOI: 10.2217/fmb-2021-0133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Leishmaniasis is a zoonotic and neglected disease, which represents an important public health problem worldwide. Different species of Leishmania are associated with different manifestations, and a practical problem that can worsen the condition of hosts infected with Leishmania is the secondary infection caused by bacteria. This review aims to examine the importance and prevalence of bacteria co-infection during leishmaniasis and the nature of this ecological relationship. In the cases discussed in this review, the facilitation phenomenon, defined as any interaction where the action of one organism has a beneficial effect on an organism of another species, was considered in the Leishmania-bacteria interaction, as well as the effects on one another and their consequences for the host.
Collapse
Affiliation(s)
- Pedro H Gallo-Francisco
- Department of Animal Biology, Biology Institute, State University of Campinas, Campinas SP, 13083-862, Brazil
| | - Marcelo Brocchi
- Department of Genetics, Microbiology & Immunology, Biology Institute, State University of Campinas, Campinas SP, Brazil
| | - Selma Giorgio
- Department of Animal Biology, Biology Institute, State University of Campinas, Campinas SP, 13083-862, Brazil
| |
Collapse
|
3
|
Sampaio RNR, Silva JSFE, Paula CDRD, Porto C, Motta JDOCD, Pereira LIDA, Martins SS, Barroso DH, Freire GSM, Gomes CM. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis. Rev Soc Bras Med Trop 2019; 52:e20180292. [PMID: 30942258 DOI: 10.1590/0037-8682-0292-2018] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Accepted: 02/18/2019] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION The treatment of mucosal leishmaniasis (ML) is difficult due to the toxicity and route of administration of standard drugs. Miltefosine is an oral agent used for leishmaniasis treatment; however, no data exist regarding its use for ML in Brazil. In this study, we aimed to evaluate the efficacy of miltefosine for ML treatment compared to that of pentavalent antimonial in a pilot study. METHODS We performed a randomized clinical trial with two parallel groups. The tested intervention consisted of miltefosine 1.3-2 mg/kg/day (two capsules) for 28 days or intravenous 20 mg SbV/kg/day of meglumine antimoniate (N-MA) for 30 days. The final endpoint was defined as complete healing of the lesion four years after treatment. We also analyzed an early endpoint at 90 days after treatment. RESULTS Forty patients were included in this study: each experimental group comprised 20 patients. Applying a multivariate model in an intention-to-treat analysis, we observed that patients treated with miltefosine had a cure probability 2.08 times greater (95% confidence interval [CI] = 1.03-4.18) than those treated with N-MA at 90 days after treatment. At the final endpoint, we observed no differences in cure probability between miltefosine and N-MA (relative risk = 0.66; 95% CI = 0.33-1.32). With respect to adverse reactions, significant differences between groups were related to gastrointestinal effects, which were more frequent in the miltefosine group. CONCLUSIONS Miltefosine may be an interesting alternative for treating ML because of its oral administration and cure rate after long-term follow-up.
Collapse
Affiliation(s)
- Raimunda Nonata Ribeiro Sampaio
- Laboratório de Dermatomicologia, Faculdade de Medicina, Universidade de Brasília, Brasília, DF, Brasil.,Hospital Universitário de Brasília, Universidade de Brasília, Brasília, DF, Brasil.,Pós-graduação Stricto Sensu em ciências da saúde, Universidade de Brasília, Brasília, DF, Brasil
| | | | | | - Cláudia Porto
- Hospital Universitário de Brasília, Universidade de Brasília, Brasília, DF, Brasil
| | | | | | - Sofia Sales Martins
- Pós-graduação Stricto Sensu em ciências da saúde, Universidade de Brasília, Brasília, DF, Brasil
| | - Daniel Holanda Barroso
- Pós-graduação Stricto Sensu em ciências da saúde, Universidade de Brasília, Brasília, DF, Brasil
| | | | - Ciro Martins Gomes
- Laboratório de Dermatomicologia, Faculdade de Medicina, Universidade de Brasília, Brasília, DF, Brasil.,Hospital Universitário de Brasília, Universidade de Brasília, Brasília, DF, Brasil
| |
Collapse
|
4
|
Machado de Machado FC, Lessa MM, Cielo CA, Souza TMDO, Prates de Souza FV, Ribeiro CS, Silva JA, Filho EMDC, Machado PRL, Montagner T, Muniz MM, Barbosa TN, Gonçalves DDS, Cincurá C. Phonotherapeutic Intervention in Patients With Mucosal Leishmaniasis Sequelae. J Voice 2019; 34:720-731. [PMID: 30795925 DOI: 10.1016/j.jvoice.2018.12.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2018] [Revised: 12/22/2018] [Accepted: 12/26/2018] [Indexed: 11/24/2022]
Abstract
PURPOSE To characterize the voice before and after speech-language intervention, with Humming nasal sound in patients with sequelae Mucosal Leishmaniasis (ML) and Cutaneous Leishmaniasis (CL). METHODS Collection of phonation /a:/ from 44 patients with ML and CL for perceptual voice analysis and computed acoustic. The Wilcoxon nonparametric test and Fisher's exact test were used, with significance level of 5%. RESULTS It was observed, prespeech therapy, that 27.7% of participants with ML presented asthenic vocal quality, and for the acoustics characteristics there was a statistically significant result for measures of frequency, frequency disturbance, noise, and subharmonic measurements, indicating phonatory instability, weakness, and noise emission giving the emission a feeling of vocal weakness. After therapy, the subharmonic segment measurements for the group with ML, showing reduction noise emission. Patients with CL had more grade 1 instability (36.4%), indicating tremor in vocal tract structures. After speech therapy, this group presented a reduction in the degree of roughness and reduction of the frequency disturbance measures, indicating a decrease in tension in the larynx and pharynx. CONCLUSION Even after completing treatment for LM, patients may experience vocal changes due to the sequelae of the disease, like vocal alterations due to nasal lesions or in other locations that interfere in the correct vocal emission. As for participants with CL, no vocal changes would be expected, since these patients present thorax, leg and arm lesions that would not cause problems for the voice. Nevertheless, the two groups of participants presented vocal changes to different degrees before vocal therapy. However, it was observed that patients with ML present vocal alterations with more severe degrees. After the speech-language intervention, the participants of both groups showed vocal improvement, but the group with CL presented more vocal benefits, possibly due to the previous vocal alterations not being so severe.
Collapse
Affiliation(s)
| | - Marcus Miranda Lessa
- Immunology Department, Edgard Santos University Hospital of the Federal University of Bahia-UFBA, Salvador, Bahia, Brazil
| | - Carla Aparecida Cielo
- Department of Speech-Language Pathology and Post-Graduation Program in Human Communication Disorders, Federal University of Santa Maria-UFSM, Santa Maria, Rio Grande do Sul, Brazil
| | | | | | | | | | - Edgar Marcelino de Carvalho Filho
- Gonçalo Muniz Institute (Fiocruz-Bahia), Immunology Service at the Edgard Santos University Hospital, Federal University of Bahia-UFBA, Salvador, Bahia, Brazil
| | - Paulo Roberto Lima Machado
- Immunology Service, Edgard Santos University Hospital of the Federal University of Bahia-UFBA, Salvador, Bahia, Brazil
| | - Thaynara Montagner
- Speech Therapist, Federal University of Santa Maria-UFSM, Santa Maria, Rio Grande do Sul
| | - Mailane Mota Muniz
- Degree in Speech Therapy, Federal University of Bahia-UFBA, Salvador, Brazil
| | | | | | - Carolina Cincurá
- Immunology Department, Edgard Santos University Hospital of the Federal University of Bahia-UFBA, Salvador, Bahia, Brazil
| |
Collapse
|
5
|
Elfaituri SS, Matoug I, Elsalheen H, Belrasali Y, Emaetig F. Mucocutaneous leishmaniasis in an 11-year-old girl with ataxia telangectasia - case report. Libyan J Med 2015; 10:26432. [PMID: 25661291 PMCID: PMC4320208 DOI: 10.3402/ljm.v10.26432] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Safa S Elfaituri
- Dermatology Department, Medical Faculty, Benghazi University, Benghazi, Libya
- Dermatology Department, Jumhoria Hospital, Benghazi, Libya;
| | - Idris Matoug
- Pediatric Department, Medical Faculty, Benghazi University, Benghazi, Libya
- Immunology and Infectious Departments, Pediatric Hospital, Benghazi, Libya
| | - Hanan Elsalheen
- Immunology and Infectious Departments, Pediatric Hospital, Benghazi, Libya
| | - Yousif Belrasali
- Immunology and Infectious Departments, Pediatric Hospital, Benghazi, Libya
| | - Fatma Emaetig
- Pathology Department, Medical Faculty, Benghazi University, Benghazi, Libya
| |
Collapse
|